Deep learning assisted non-invasive lymph node burden evaluation and CDK4/6i administration in luminal breast cancer

Summary: Precise lymph node evaluation is fundamental to optimize CDK4/6 inhibitor therapy in luminal breast cancer, particularly given contemporary trends toward axillary surgery de-escalation that may compromise traditional lymph node staging for recurrence risk evaluation. The lymph node predicti...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuhan Liu, Jinlin Ye, Zecheng He, Mingyue Wang, Changjun Wang, Jie Lang, Yidong Zhou, Wei Zhang
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:iScience
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004225011101
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849433962798120960
author Yuhan Liu
Jinlin Ye
Zecheng He
Mingyue Wang
Changjun Wang
Jie Lang
Yidong Zhou
Wei Zhang
author_facet Yuhan Liu
Jinlin Ye
Zecheng He
Mingyue Wang
Changjun Wang
Jie Lang
Yidong Zhou
Wei Zhang
author_sort Yuhan Liu
collection DOAJ
description Summary: Precise lymph node evaluation is fundamental to optimize CDK4/6 inhibitor therapy in luminal breast cancer, particularly given contemporary trends toward axillary surgery de-escalation that may compromise traditional lymph node staging for recurrence risk evaluation. The lymph node prediction network (LNPN) was developed as a multi-modal model incorporating both clinicopathological parameters and ultrasonographic characteristics for lymph node burden differentiation. In a multicenter cohort of 411 patients, LNPN demonstrated robust performance, achieving an AUC of 0.92 for binary lymph node burden classification (N0 vs. N+) and 0.82 for ternary lymph node burden classification (N0/N1–3/N ≥ 4). Notably, among patients undergoing sentinel lymph node biopsy (SLNB) with confirmed 1–2 metastatic lymph nodes, LNPN predicted high-burden metastases (N ≥ 4) with an AUC of 0.77. LNPN provided a non-invasive method to assess lymph node metastasis and recurrence risk, potentially reducing unnecessary axillary lymph node dissection (ALND), and facilitating decision-making regarding the intervention of CDK4/6i in luminal breast cancer patients.
format Article
id doaj-art-15dbff89b06146b48aa167a320c8d0d5
institution Kabale University
issn 2589-0042
language English
publishDate 2025-07-01
publisher Elsevier
record_format Article
series iScience
spelling doaj-art-15dbff89b06146b48aa167a320c8d0d52025-08-20T03:26:51ZengElsevieriScience2589-00422025-07-0128711284910.1016/j.isci.2025.112849Deep learning assisted non-invasive lymph node burden evaluation and CDK4/6i administration in luminal breast cancerYuhan Liu0Jinlin Ye1Zecheng He2Mingyue Wang3Changjun Wang4Jie Lang5Yidong Zhou6Wei Zhang7Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaSchool of Artificial Intelligence, Hebei University of Technology, Tianjin, ChinaDepartment of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Corresponding authorDepartment of Breast Surgery, Beijing Longfu Hospital, Beijing, China; Corresponding authorDepartment of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Corresponding authorSchool of Artificial Intelligence, Hebei University of Technology, Tianjin, China; Corresponding authorSummary: Precise lymph node evaluation is fundamental to optimize CDK4/6 inhibitor therapy in luminal breast cancer, particularly given contemporary trends toward axillary surgery de-escalation that may compromise traditional lymph node staging for recurrence risk evaluation. The lymph node prediction network (LNPN) was developed as a multi-modal model incorporating both clinicopathological parameters and ultrasonographic characteristics for lymph node burden differentiation. In a multicenter cohort of 411 patients, LNPN demonstrated robust performance, achieving an AUC of 0.92 for binary lymph node burden classification (N0 vs. N+) and 0.82 for ternary lymph node burden classification (N0/N1–3/N ≥ 4). Notably, among patients undergoing sentinel lymph node biopsy (SLNB) with confirmed 1–2 metastatic lymph nodes, LNPN predicted high-burden metastases (N ≥ 4) with an AUC of 0.77. LNPN provided a non-invasive method to assess lymph node metastasis and recurrence risk, potentially reducing unnecessary axillary lymph node dissection (ALND), and facilitating decision-making regarding the intervention of CDK4/6i in luminal breast cancer patients.http://www.sciencedirect.com/science/article/pii/S2589004225011101CancerMachine learning
spellingShingle Yuhan Liu
Jinlin Ye
Zecheng He
Mingyue Wang
Changjun Wang
Jie Lang
Yidong Zhou
Wei Zhang
Deep learning assisted non-invasive lymph node burden evaluation and CDK4/6i administration in luminal breast cancer
iScience
Cancer
Machine learning
title Deep learning assisted non-invasive lymph node burden evaluation and CDK4/6i administration in luminal breast cancer
title_full Deep learning assisted non-invasive lymph node burden evaluation and CDK4/6i administration in luminal breast cancer
title_fullStr Deep learning assisted non-invasive lymph node burden evaluation and CDK4/6i administration in luminal breast cancer
title_full_unstemmed Deep learning assisted non-invasive lymph node burden evaluation and CDK4/6i administration in luminal breast cancer
title_short Deep learning assisted non-invasive lymph node burden evaluation and CDK4/6i administration in luminal breast cancer
title_sort deep learning assisted non invasive lymph node burden evaluation and cdk4 6i administration in luminal breast cancer
topic Cancer
Machine learning
url http://www.sciencedirect.com/science/article/pii/S2589004225011101
work_keys_str_mv AT yuhanliu deeplearningassistednoninvasivelymphnodeburdenevaluationandcdk46iadministrationinluminalbreastcancer
AT jinlinye deeplearningassistednoninvasivelymphnodeburdenevaluationandcdk46iadministrationinluminalbreastcancer
AT zechenghe deeplearningassistednoninvasivelymphnodeburdenevaluationandcdk46iadministrationinluminalbreastcancer
AT mingyuewang deeplearningassistednoninvasivelymphnodeburdenevaluationandcdk46iadministrationinluminalbreastcancer
AT changjunwang deeplearningassistednoninvasivelymphnodeburdenevaluationandcdk46iadministrationinluminalbreastcancer
AT jielang deeplearningassistednoninvasivelymphnodeburdenevaluationandcdk46iadministrationinluminalbreastcancer
AT yidongzhou deeplearningassistednoninvasivelymphnodeburdenevaluationandcdk46iadministrationinluminalbreastcancer
AT weizhang deeplearningassistednoninvasivelymphnodeburdenevaluationandcdk46iadministrationinluminalbreastcancer